LAS VEGAS, Feb. 11, 2021
- Thrombocytopenia Treatment Market is expected to experience robust expansion due to the rise in patient pool and availability of products
LAS VEGAS, Feb. 11, 2021 /PRNewswire/ --DelveInsight's "Thrombocytopenia Market" report provides a thorough comprehension of the Thrombocytopenia, historical and forecasted epidemiology, and the Thrombocytopenia market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Thrombocytopenia market report also proffers an analysis of recent Thrombocytopenia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs.
Some of the vital points from the Thrombocytopenia Market Research Report
For additional information on Market Impact by Therapies, visit: Thrombocytopenia Therapeutics Market Analysis
Thrombocytopenia is a condition in which the blood has a lower than a normal number of platelets. The condition can be inherited or acquired. Thrombocytopenia causes, sometimes, are not known. The main Thrombocytopenia symptoms include mild-to-severe bleeding. Bleeding can occur inside the body or underneath the skin, or from the skin's surface. As per DelveInsight's analysts, the total number of Thrombocytopenia cases in the 7MM was 1,653,934 in 2020. The Thrombocytopenia cases are expected to increase throughout the study period of 2018–2030 with a decent CAGR.
The Thrombocytopenia Market Report provides historical as well as forecasted epidemiological analysis segmented into:
Request sample report for more insights @ Thrombocytopenia Market Insight
Thrombocytopenia treatment depends on its cause and severity. The main goal of Thrombocytopenia treatment is to prevent death and disability caused by bleeding. If the condition is mild, the patient may not need treatment.
One treatment approach is a direct treatment to the etiology of thrombocytopenia. Unfortunately, only in a minority of cases is the etiology of thrombocytopenia exact and the cause found. In a case of severe bleeding, if the thrombocytopenia etiology is not known but not thought to be immunologic, platelet transfusion can be used to proffer an immediate platelet increase.
Patients with inherited thrombocytopenia have been treated with platelet transfusions. The option of allogeneic stem cell transplantation is reserved for inherited thrombocytopenia with a high risk of marrow failure or a rising risk of acute leukemia.
Many Immune Thrombocytopenia cases (ITP) can be left untreated, and spontaneous remission in children is common. If therapy is required, the first-line treatment option is generally corticosteroids. The most effective second-line treatment option is splenectomy. Further, second-line treatment options with documented evidence of efficacy comprise various agents: azathioprine, cyclosporine, cyclophosphamide, danazol, dexamethasone, vinca alkaloids, mycophenolate mofetil, rituximab, and thrombopoietin-receptor agonists.
The use of thrombopoietin-receptor agonists is an effective and safe second-line treatment strategy. Two thrombopoietin-receptor agonists were authorized to treat chronic ITP in adults by the US Food and Drug Administration (FDA) in 2008 and have been utilized extensively for chronic ITP treatment in relapsed and refractory patients. These were romiplostim, a thrombopoietin mimetic formed from peptides (peptibody), and eltrombopag (a small molecule, non-peptide).
The mainstay of Thrombotic Thrombocytopenic Purpura (TTP) treatment is plasmapheresis with plasma replacement. Other treatment modalities in non-responders to plasmapheresis include immune-suppression, not limited to high dose steroids and B-cell depleting agents (e.g., rituximab).
Thrombocytopenia Emerging Therapies Along with Key Players
Thrombocytopenia pipeline possesses potential drugs in mid-stage developments to be approved soon. The major key players enumerated below can create a significant positive shift in Thrombocytopenia market size.
Concluding thoughts on Thrombocytopenia Market Growth
Scope of the Thrombocytopenia Market Insight
Request for a Webex demo of the report @ Thrombocytopenia Market Size Analysis
Table of Contents
Key Insights on Thrombocytopenia
Executive Summary of Thrombocytopenia
Thrombocytopenia Market Overview at a Glance
Disease Background and Overview: Thrombocytopenia
Thrombocytopenia Patient Journey
Thrombocytopenia Epidemiology and Patient Population
United States Epidemiology
EU5 Countries Epidemiology
Thrombocytopenia Unmet Needs
Thrombocytopenia Marketed Drugs
Cablivi (Caplacizumab/ALX-0081): Sanofi (Ablynx)
Tavalisse (Fostamatinib): Rigel Pharmaceuticals/Kissei Pharmaceutical
Doptelet (Avatrombopag): Sobi (Dova Pharmaceuticals)
Mulpleta/Mulpleo (Lusutrombopag): Shionogi & Co., Ltd.
Nplate (Romiplostim, AMG-531): Amgen
Promacta (eltrombopag): Novartis
Rituxan (rituximab): Zenyaku Kogyo
Thrombocytopenia Emerging Drugs
Key Cross Competition
Rozanolixizumab (UCB7665): UCB Biopharma
Rilzabrutinib (PRN-1008): Principia Biopharma
TAK-755 (BAX930/SHP655): Baxalta/Takeda
Efgartigimod (ARGX-113): Argenx
GC5101B (GC5107A, IV-Globulin SN Inj. 10%): GC Pharma
Narsoplimab (OMS721): Omeros Corporation
TAK-079: Millennium Pharmaceuticals/Takeda
M254 (Hypersialylated IgG): Momenta Pharmaceuticals
Interleukin 2: ILTOO Pharma
SKI-O-703: Genosco (Subsidiary of Oscotec)
7MM Thrombocytopenia Market Analysis
United States Thrombocytopenia Market Outlook
EU-5 Thrombocytopenia Market Outlook
Germany Market Size
France Market Size
Italy Market Size
Spain Market Size
United Kingdom Market Size
Japan Thrombocytopenia Market Outlook
Thrombocytopenia Market Drivers
Thrombocytopenia Market Barriers
Reimbursement and Thrombocytopenia Market Access
Browse detailed TOC with charts, figures, tables @ Thrombocytopenia Market Size Report
View Related Reports
DelveInsight's Thrombocytopenia - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Thrombocytopenia in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Thrombocytopenia Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Thrombocytopenia market.
Thrombocytopenia - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020 " report by DelveInsight offers comprehensive insights on marketed and Phase III products for Thrombocytopenia.
DelveInsight's Chemotherapy-induced thrombocytopenia (CIT) - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.
DelveInsight's Immune Thrombocytopenia (ITP) - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.
DelveInsight' s Idiopathic Thrombocytopenic Purpura - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.
DelveInsight's Endocarditis disease Market Insights, Epidemiology and Market Forecast - 2030 report provides an in-depth understanding of historical and forecasted epidemiology.
DelveInsight' s Community-Acquired Bacterial Pneumonia (CABP) - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and in-depth understanding of historical and forecasted epidemiology.
Ambulatory Arrhythmia Monitoring Devices Market Insights, Competitive Landscape and Market Forecast-2025 report delivers an in-depth understanding of Ambulatory Arrhythmia Monitoring Devices.
Neuroendoscopy Market Market Insights, Competitive Landscape and Market Forecast-2025 report delivers an in-depth understanding of the Neuroendoscopy Market and the historical and forecasted epidemiology.
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.